Results 221 to 230 of about 4,987 (254)
Some of the next articles are maybe not open access.
Citicoline is not protective in experimental models of Huntington's disease
Neurobiology of Aging, 2007We have evaluated the neuroprotective effects of citicoline in relevant phenotypic models of Huntington's disease induced by either the mitochondrial inhibitor 3-nitropropionic acid or the N-methyl-D-aspartate agonist quinolinic acid, which, respectively, reproduce the metabolic defect or the excitotoxicity seen in the disease. We found that citicoline
Mievis, Stéphane +5 more
openaire +3 more sources
Citicoline in the treatment of Parkinson's disease.
Clinical therapeutics, 1991The subjects were 20 patients with Parkinson's disease. They were aged 52 to 76 years and the duration of the disease ranged from four to 25 years (mean, 12.5 years). All the patients were receiving levodopa alone or in combination with tricyclic antidepressants, amantadine, bromocriptine, anticholinergic agents, or lisuride.
J F, Martí Massó, M, Urtasun
openaire +3 more sources
Citicoline. Ferrer Internacional.
Current opinion in investigational drugs (London, England : 2000), 2002Citicoline was originally developed and launched by Ferrer for the treatment of stroke, and is now also being investigated for the potential treatment of Alzheimer's disease (AD). In the US, the compound is being developed by Interneuron for the treatment of stroke.
openaire +1 more source
Citicoline as Adjuvant Therapy in Parkinson's Disease: A Systematic Review
Clinical Therapeutics, 2021Roland Dominic G Jamora
exaly